Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder

• Status: Completed
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is a Phase 2 trial to test the efficacy of LY686017 in the treatment of Social Anxiety Disorder.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Paroxetine

Criteria

Inclusion Criteria:

• Male or female outpatients at least 18 years of age and not more than 65 years of age.

• Must sign the informed consent document.

• Present at Visit 1 with social anxiety disorder based on a Clinical Global Impression-Severity score of greater than or equal to 4.

• Females of childbearing potential (not surgically sterilized and between menarche and 1 year post-menopause) must test negative for pregnancy at the time of enrollment based on a urine pregnancy test and agree to use both a reliable primary method of birth control.

• Judged to be reliable and willing to keep all appointments for clinic visits, tests, and procedures required by the protocol.

Exclusion Criteria:

• Have any comorbid Axis I disorders (such as major depression, obsessive compulsive disorder, post-traumatic stress disorder, or panic disorder), in the opinion of the investigator, if the disorder occurred within the last 6 months.

• Have had any previous or current diagnoses of bipolar disorders, schizophrenia, or other psychotic disorders.

• Have the presence of an Axis II disorder, except avoidant personality disorder.

• Have a serious medical illness.

• Have abnormal thyroid-stimulating hormone (TSH) concentrations or are taking thyroid supplements.